Discover Great Companies Discover Great Clients
Popularity  2.4万   |   Followers  57   |   Likes  28   |   Feedback  44
Shanghai Pudong New District Yao Products R&D Biotechnology Pharmaceuticals Ji Shu Zhuan Yi Yi Yao Chuang Xin Yi Yao Ji Group Zhong Pharmaceuticals Chemistry Pharmaceutical CRO Services Medical Products Pharmaceutical Contracts R&D Hua Gong / Chemistry Zhuan Hua Yi Xue 发明专利 博士后工作站 自主创新示范企业 国家科技进步奖 高新技术企业 省级高新技术企业
More

Company Overview

  • Nature: Listed Company Size: 500-999 employees Status: 注销
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: Shanghai New Origin Pharmaceutical Group Co., Ltd.。

Development Stage

  • Honors: 发明专利 博士后工作站 According to algorithm

About the Company

Shanghai New Origin Pharmaceutical Group was established in 2001, located in Zhangjiang Medicine Valley, Pudong. It successively established branches in Taizhou, Wuhan, Wenzhou, and Guangzhou. In 2015, it became a wholly-owned subsidiary of Zhejiang Yatai Pharmaceutical (Shenzhen Stock Exchange code 002370). New Origin is a high-tech enterprise with the philosophy of realizing a healthy China and an innovative China, committed to serving the industrialization of innovative achievements, capitalizing on entrepreneurial ventures for transformation, and accelerating the internationalization of the health industry. New Origin's mission: accelerate the industrialization, marketization, and capitalization of innovative technologies. New Origin provides: one-stop professional services CHO for health and medical products. New Origin establishes: public service platform PCR for the health and medical industry chain. New Origin integrates: government, industry, medical, research, and capital resources for the development of the big health industry. New Origin's culture: entrepreneurial passion, innovative vitality, and excellence-creating mechanisms. 1. Main business of New Origin: pioneering the provision of full-process CRO services covering health and medical products. Service products include: pharmaceuticals (biological products, chemical drugs, natural medicines), medical devices (diagnostic reagents, medical equipment, medical consumables), and clinical diagnosis and treatment technologies; an industry-medicine-research collaborative innovation service model centered on the major disease prevention and control science and technology action plan. Commissioned by the Medical Science and Technology Development Research Center of the National Health and Family Planning Commission, New Origin undertakes the research, promotion, and service work of the major disease prevention and control science and technology action plan. 2. Advantages of New Origin: Large platform for technical services: New Origin has established a large platform for industry-medicine-research collaborative innovation services by integrating GLP, GCP, and GMP alliance resources in a GRDP manner. Preclinical research service platform for new drugs: China GLP Institution Alliance. Pilot-to-industrialization research service platform for new drugs: International Alliance for Pharmaceutical Industry-University-Research (GMP). Clinical research and promotion service platform for new drugs: Wenzhou Innovation and Collaboration Center, Translational Medicine Center of Guangdong Academy of Medical Sciences (GCP). Integrated innovation and entrepreneurship service platform: Relying on national industrial bases, New Origin builds innovation and entrepreneurship service platforms, achieving institutional and mechanism innovation integrating government, industry, medicine, research, and capital, and providing one-stop services for health and medical products and technologies. Wuhan Optics Valley New Drug Entrepreneurship Incubator (first batch of resident enterprises in 2009). China Pharmaceutical City Enterprise Incubation and Industrialization Base (first batch of resident enterprises in 2007). Wenzhou Yueqing Medical Island Town New Drug Industrialization Base. International medical service platform for health care: Shanghai Zhangjiang Medicine Valley Antibody and Personalized R&D Diagnosis and Treatment Center, Wenzhou Health Town. Special fund for major disease prevention and control and national special awards under the Achievement Transformation and Investment and Financing Promotion Alliance. Excellence-creating mechanisms integrate resources for the development of the big health industry from government, industry, medicine, research, and capital. 3. Company qualifications: Member of China Medicinal Biotechnology Association; National Shanghai Patent Technology Display and Trading Center; Post-doctoral scientific research workstation. Realize the value of biomedicine and strive to scale new heights in the bio-industry.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

New Origin Pharmaceutical honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Business Registration

Provided by

Operating Status: 注销
Registered Capital: 10,000万(元)
Legal Representative: 任军
Date Established:
Credit Code: 913100007824010512
Registered Address: 中国(上海)自由贸易试验区蔡伦路780号208室

Discover Great Companies, Discover Great Clients

上海公司名录 上海“Pudong New Area”公司名录 上海“药物研发”公司名录 上海“生物医药”公司名录 上海“新药研发”公司名录 上海“CRO”公司名录 上海“基因工程”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates